- Home
- SSM vs KZIA Comparison
SSM vs KZIA Comparison
Compare SSM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSM
- KZIA
- Stock Information
- Founded
- SSM N/A
- KZIA 1994
- Country
- SSM Germany
- KZIA Australia
- Employees
- SSM 43
- KZIA N/A
- Industry
- SSM
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SSM
- KZIA Health Care
- Exchange
- SSM Nasdaq
- KZIA Nasdaq
- Market Cap
- SSM 9.9M
- KZIA 9.6M
- IPO Year
- SSM N/A
- KZIA 1999
- Fundamental
- Price
- SSM $6.64
- KZIA $8.60
- Analyst Decision
- SSM
- KZIA Strong Buy
- Analyst Count
- SSM 0
- KZIA 3
- Target Price
- SSM N/A
- KZIA $16.00
- AVG Volume (30 Days)
- SSM N/A
- KZIA 1.8M
- Earning Date
- SSM N/A
- KZIA 12-26-2025
- Dividend Yield
- SSM N/A
- KZIA N/A
- EPS Growth
- SSM N/A
- KZIA N/A
- EPS
- SSM N/A
- KZIA N/A
- Revenue
- SSM N/A
- KZIA $1,199,108.00
- Revenue This Year
- SSM N/A
- KZIA N/A
- Revenue Next Year
- SSM N/A
- KZIA N/A
- P/E Ratio
- SSM N/A
- KZIA N/A
- Revenue Growth
- SSM N/A
- KZIA N/A
- 52 Week Low
- SSM N/A
- KZIA $2.86
- 52 Week High
- SSM N/A
- KZIA $29.30
- Technical
- Relative Strength Index (RSI)
- SSM N/A
- KZIA 61.89
- Support Level
- SSM N/A
- KZIA $7.09
- Resistance Level
- SSM N/A
- KZIA $8.75
- Average True Range (ATR)
- SSM 0.00
- KZIA 0.64
- MACD
- SSM 0.00
- KZIA 0.14
- Stochastic Oscillator
- SSM 0.00
- KZIA 94.33
About SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.